Canterbury University spin-out Tiro Lifesciences aims to transform breast cancer screening with $600,000.
New Zealand-based Tiro Lifesciences, a spin-out of Canterbury University, has raised NZD 600,000 ($443,000) to commercialise breast cancer screening technology.
New Zealand has one of the highest rates of breast cancer in the world, and is the second most common cause of cancer-related death in women in the country, with 2,700 diagnosed each year. Roughly 40% of women have dense breast tissue, which both increases the risk of breast cancer but also makes it harder to screen for via X-ray…
